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Background: PPP2R2A deletions were recently linked to a subgroup of luminal breast carcinoma (BC) that exhibits
poor survival. This subgroup also exhibited amplification of a chromosome region containing the Cyclin D1 coding
gene, CCND1. Therefore, we aimed to investigate whether a combination of PPP2R2A (B55α) and Cyclin D1
expression statuses evaluated by immunohistochemistry (IHC) could define a subgroup of luminal BC that exhibits
poor survival.
Methods: First we conducted a retrospective cohort study using sequencing data from The Cancer Genome Atlas
initiative to correlate PPP2R2A copy number alteration (CNA) status with its expression level and the corresponding
overall survival (OS). Next, also using a retrospective cohort study design, we evaluated the PPP2R2A (B55α)
expression levels by IHC in a total of 807 BC patients from two independent cohorts (discovery cohort n = 349
and validation cohort n = 458). Cyclin D1 expression was also evaluated, and the PPP2R2A (B55α)-/low/Cyclin
D1high phenotype was evaluated as a predictor of disease-free survival (DFS) and OS in luminal-like BC patients.
Results: Deletions in the PPP2R2A gene strongly correlate with lower mRNA expression and poorer OS. PPP2R2A
(B55α)-/low carcinomas have significantly shorter DFS and OS. Furthermore, in univariate analysis, the PPP2R2A
(B55α)-/low/Cyclin D1high phenotype is significantly associated with poorer DFS and OS. In a multivariate analysis,
the PPP2R2A (B55α)-/low/Cyclin D1high phenotype is significantly associated with poor DFS, thus defining a group
of luminal-like BC with higher risk of relapse.
Conclusion: We demonstrate that BCs harboring PPP2R2A deletions are associated with worse OS. Moreover, this
is the first study to demonstrate that the combination of altered PPP2R2A (B55α) and high Cyclin D1 expression
by IHC defines a subgroup of luminal-like BC patients with a high risk of relapse and death.
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PP2A (Protein Phosphatase 2) is a major heterotrimeric
serine/threonine phosphatase that consists of one structural
(PP2A/A), one catalytic (PP2A/C) and one regulatory
(PP2A/B) subunit [1]. The PP2A/A and PP2A/C subunits
each have two known isoforms (α, β) and comprise the core
dimer (reviewed in [2]). Conversely, the PP2A/B subunit
has multiple isoforms, and it is the major determinant of
substrate specificity [3]. As a Ser/Thr phosphatase, PP2A* Correspondence: fschmitt@ipatimup.pt
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unless otherwise stated.counteracts the actions of Ser/Thr kinases, which are often
defective or deregulated in cancer. Examples include com-
ponents of the MAP kinase and AKT pathways, the tumor
suppressors pRB and p53, and CDK1 substrates (reviewed
in [2]).
Substantial evidence points to a role for PP2A as a
tumor suppressor. Early studies showed that toxin-
mediated inhibition of PP2A was a potent tumor-
promoter stimulus and that PP2A had a pivotal role in
modulating the transforming ability of oncogenic viruses
[4,5]. More recent reports have demonstrated that PP2A
is inhibited in colorectal carcinoma [6]. Such inhibition
is due, at least partially, to the downregulation of somehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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and PPP2R2A genes [6]. Alterations in PPP2R5E have
also recently been shown to be a driver of clonal evolu-
tion in breast carcinoma [7]. Specifically, PPP2R2A is
located on chromosome 8p21.2 and encodes B55α, a B
regulatory subunit of PP2A. Loss of PPP2R2A is a com-
mon event in non-small cell lung cancer, and it results
in the impairment of the homologous recombination
repair pathway [8]. Additionally, shRNA-mediated si-
lencing of PPP2R2A has been shown to be a potent
oncogenic signal in experimental models of colon car-
cinoma [8]. Furthermore, in patients with acute mye-
loid leukemia (AML), low levels of B55α expression in
blast cells have been associated with shorter complete
remission duration, demonstrating that in AML, the
decreased expression of PPP2R2A (B55α) is an adverse
prognostic factor [9]. Taken together, these findings
lead to the conclusion that PP2A, as well as some of its
regulatory subunits, such as PPP2R2A, have definitive
roles as tumor suppressors in a large variety of cancers.
In breast carcinoma (BC), the expression status and
genomic alterations of PP2A and it subunits, such as
PPP2R2A, are only now being elucidated. Despite re-
cent reports of the possible therapeutic targeting of
PP2A with inhibitors in BC [10], knowledge is still lim-
ited. Different haplotypes of PPP2R2A modify BC risk
[11], but mutations in PPP2R2A are rarely detected in
BC (The Cancer Genome Atlas Research Network
BRCA dataset, provisional). More interestingly, in a re-
cent study, copy number aberrations (CNAs) centered
on PPP2R2A, along with heterozygous and homozygous
deletions were commonly found in BC, and they were
associated with a mitotically active estrogen receptor
(ER)-positive BC subgroup [12]. The same study also
identified an ER-positive BC subgroup, comprising
11q13/14 cis-acting luminal tumors that exhibited a
steep mortality trajectory with elevated hazard ratios
(Integrative Custer 2) [12]. The CNAs within this sub-
group also contain the amplification of a region at
11q13 that harbors the Cyclin D1-encoding gene
CCND1 [12]. Nevertheless, rapid translation of these
findings to a clinical setting has been limited because of
the need to use genomic and transcriptomic profiling,
technologies that are not routinely available in most
pathology laboratories.
Here, we test the hypothesis that PPP2R2A protein
expression, detected using immunohistochemistry
(IHC), will uncover a group of ER-positive BCs that
exhibit a differential outcome. Additionally, we hy-
pothesized that the combined assessment of
PPP2R2A and Cyclin D1 protein expression would
further refine the subgroups’ outcome associations
and be potentially useful in identifying Integrative
Cluster 2-like BC.Methods
The Cancer Genome Atlas (TCGA) data
Data from the Invasive Breast Cancer dataset (TCGA,
Provisional) of the TCGA database on PPP2R2A mRNA
expression levels as determined by RNA sequencing
(RNA Seq V2 RSEM - Illumina HiSeq 2000 platform),
copy number alteration (CNA) as determined by GISTIC
2.0 analysis, recurrence status and overall survival (OS)
were downloaded from the cBIO Cancer Genomics Portal
on March 24, 2014 [13,14]. Survival analysis was per-
formed by comparing patients with no CNAs with those
with heterozygous or homozygous deletions.Patient samples
Additionally we used the two following independent co-
horts of clinical samples: (a) a discovery cohort com-
prised of 349 non-consecutive, randomly selected
patients with BC who had undergone surgery at Centro
Hospitalar de São João, EPE, Porto, Portugal, between
January 2001 and March 2006; (b) a validation cohort
comprised of 458 non-consecutive, randomly selected
patients with BC who had undergone surgery between
1978 and 1992 at the Hospital Xeral-Cíes, Vigo, Spain.
Only patients with histologically confirmed BC from
which adequate formalin-fixed, paraffin-embedded tissue
was available were included. The tumor grade was deter-
mined according to the modified Bloom and Richardson
classification [15]. The exclusion criteria were similar for
both cohorts and included the following requirements:
previous history of BC, hereditary BC, bilateral BC at
diagnosis, refusal of surgical treatment, synchronous tu-
mors and cases with neoadjuvant therapy as the initial
treatment. All estrogen receptor (ER)-negative and
lymph node (LN)-positive patients in the discovery co-
hort had received adjuvant chemotherapy. None of the
HER2+ patients had received trastuzumab as the ini-
tial treatment. The clinical definitions used for OS
and Disease-Free Survival (DFS) are detailed in the
Additional file 1. Women in whom the envisaged end-
point was not reached were censored as of the last
follow-up date. Subjects with missing values for sur-
vival and PPP2R2A (B55α) expression in both cohorts
were excluded from the analyses. A diagram of the
complete analytical strategy and the flow of patients
through the study, including the numbers of patients
included in each stage of the analysis, are shown in
Figure 1.
This study was conducted according to the Portuguese
National Regulative Law for the handling of biological
specimens from tumor banks (waiving the need of spe-
cify approval for samples from a tumor archive and
used in retrospective analysis) and complied with The
Helsinki Declaration statement.
Figure 1 Diagram illustrating the analysis strategy and number of patients included at each step.
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Representative areas of invasive BCs were selected on
hematoxylin and eosin (H&E)-stained sections, and two
tissue cores (2 mm in diameter) were obtained from
each specimen for TMA construction as previously de-
scribed [16]. An H&E-stained section from each TMA
block was reviewed to confirm the presence of morpho-
logically representative areas of the original lesions. Ap-
propriate controls with normal breast tissue were also
included. After pretreatment and antigen retrieval, the
slides were incubated with the primary antibodies for
PPP2R (sc-81606; Santa Cruz Biotechnology, diluted
1:50) and Cyclin D1 (SP4; Neomarkers, diluted 1:50).
For the discovery cohort, clinicopathological data were
obtained from original pathology reports and Ki-67 IHC
performed in cases missing this information. ER, PgR,
Her2 and Ki-67 IHC were performed on the validation
cohort, and used as surrogates for molecular subtyping,
based on 13th St Gallen International Breast Cancer
Conference (2013) Expert Panel recommendations [17].
The cut-off level for ER and PgR receptor positivity was
nuclear staining in more than 1% of tumor cells, and the
cut-off level for Ki-67 was based on work described in
Cheang et al. [18]. In both cohorts, HER2 evaluation
was carried out in compliance with the most recent
American Society of Clinical Oncology/College of
American Pathologists (ASCO/CAP) guidelines [19].The details regarding TMA construction, antibodies
used and the detailed conditions for each antibody, in-
cluding those targeting PPP2R2A (B55α) and Cyclin D1,
are included in the supplementary data (Additional file
1: Table S1). All morphological and IHC assessments
were made by a pathologist (FS). Cyclin D1 expression
was determined as previously described [20].
PPP2R2A (B55α) scoring
Because to the best of our knowledge there is no pub-
lished data regarding a PPP2R2A (B55α) scoring method
in BC, we first used the discovery cohort to establish the
ideal assessment criteria for PPP2R2A (B55α) expression
by IHC and applied the same methodology to the valid-
ation cohort. Briefly, PPP2R2A (B55α) IHC expression
was semi-quantitatively evaluated in the cytoplasm of in-
vasive carcinoma according to previous methodology
[21]. Afterwards, using the minimum p-value method on
the log-rank test for OS in the discovery cohort, we de-
termined the ideal cut-off for dichotomization of
PPP2R2A (B55α) scoring (further details are provided in
the Additional file 1) [22]. After establishing the IHC as-
sessment criteria in the discovery cohort, expression in
the validation cohort was determined using the same
methodology. Briefly, tumors were considered PPP2R2A
(B55α)-/low when there was no detectable expression or
if it was weak in less than 5% of tumor cells (Figure 2).
Figure 2 Two examples of PPP2R2A (B55α) IHC expression. PPP2R2A (B55α)high expression in a low-grade carcinoma (a, 4×; b, 400×); PPP2R2A
(B55α)-/low expression in a high grade carcinoma (c, 100×).
Figure 3 Expression levels of PPP2R2A according to CNA. Using
data from the TCGA database, the expression levels of PPP2R2A
were plotted according to the following classifications of gene copy
number: normal (n = 278), heterozygous deletion (HetDel) (n = 411)
or homozygous deletion (HomDel) (n = 47). Significant differential
expression was observed for all pair-wise comparisons using
Student’st-test (p-value <0.001 for all comparisons), showing a positive
relationship between copy number and gene expression.
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Where appropriate, Pearson’s χ2, Fisher’s exact and Stu-
dent’s t tests were used. Cumulative survival probabilities
were estimated using the Kaplan–Meier method, and
differences between survival rates were tested for signifi-
cance using the log-rank test. Multivariate analysis for
survival was performed using the Cox proportional haz-
ards model. Variables included in the models were de-
fined a priori and are indicated under each table.
Departures from the proportional hazards assumption
were assessed based on the Schoenfeld residuals. Hazard
ratios (HR) and 95% confidence intervals (95% CI) were
estimated for each variable. All tests were two-sided with
a 95% CI and a p-value of < 0.05 considered significant.
Correction for multiple comparisons was performed
where indicated using the Benjamini-Hochberg procedure.
TCGA data were analyzed using R Version 3.0.2 for Mac
OS X, and all other statistical analysis were carried out
using Stata® software, version 13.
All analyses and data reporting were performed ac-
cording to the “REporting recommendations for tumour
MARKer prognostic studies” (REMARK) guidelines and
STrengthening the Reporting of OBservational studies in
Epidemiology (Additional file 2) statement [23,24].
Results
PPP2R2A CNA status is associated with mRNA expression
levels and OS in the TCGA dataset
To investigate whether there was a correlation between
CNA and PPP2R2A expression, namely if CNA with any
deletion was associated with lower PPPR2A expression
levels, data for 852 BC samples were retrieved from
TCGA. We selected the cases displaying either normal
copy number, heterozygous PPP2R2A deletion or homo-
zygous deletion (n = 736) for further analysis. Cases dis-
playing either heterozygous or homozygous deletions at
the PPP2R2A gene locus constituted 53.8% (n = 458) of
all cases. The PPP2R2A mRNA expression level shows a
significant association with CNA, with cases with het-
erozygous or homozygous deletion of the PPP2R2Alocus displaying a significantly lower mRNA expression
Z-Score (Figure 3). The p-values of the t-test performed
for every pairwise comparison were <0.001, after multipli-
city correction using the Benjamini-Hochberg procedure.
Using the same dataset (Invasive Breast Cancer data-
set, TCGA, provisional), we performed survival analysis
on all cases available with CNA data (either HomDel or
HetDel) and survival information (n = 582 patients). We
compared the OS of patients with CNA (n = 374, 33 re-
ported events) with those without CNA at the PPP2R2A
locus (n = 208, 9 reported events) and show that patients
with CNA at PPP2R2A have significantly worse survival
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0.047) (Figure 4). Due to the extensive follow-up time
and unavailability of the time to progression in the cur-
rently publically available version of the dataset, we used
the Wilcoxon test because we considered the earlier
events to have occurred due to disease recurrence. We
performed a sensitivity analysis that supports the as-
sumption that disease-specific events occurred earlier
(more details in Additional file 1: Figure S1).
PPP2R2A (B55α)-/low expression is associated with higher
grade and ER positive carcinomas
In this study, we included 280 tumors from the discovery
cohort and 378 from the validation cohort that had
PPP2R2A (B55α) expression and outcome data. A
summary of the patients’ characteristics is provided in
Additional file 1: Table S3 for the discovery cohort and
in Additional file 1: Table S4 for the validation cohort.
The prevalence of carcinomas with PPP2R2A (B55α) -/low
expression was similar in both cohorts, with 51.8% (n =
145) and 54.0% (n = 204) of tumors expressing PPP2R2A
(B55α) in the discovery and validation cohorts, respect-
ively. In the discovery cohort, tumors displaying
PPP2R2A (B55α) -/low expression are associated with
ER expression (p < 0.001), higher grade (p = 0.004) and
Her2 overexpression (p < 0.001). Tumors displaying
PPP2R2A (B55α)-/low expression are also associated
with shortened DFS and OS (log-rank p < 0.001 and p =
0.002, respectively) (Additional file 1: Table S3). Associa-
tions between PPP2R2A (B55α) -/low expression and ER
expression and short DFS and OS were further confirmedFigure 4 Survival probability according to CNA on PPP2R2A loci. In the TC
the PPP2R2A locus (n = 374) display significantly shorter OS (Wilcoxon p = 0in the validation cohort (p = 0.001 for ER; log-rank p =
0.006 for DFS and p =0.033 for OS) (Additional file 1:
Table S4).
Due to the hypothesis set a priori regarding the associ-
ation between PPP2R2A (B55α) expression and ER status,
which was subsequently tested on the two independent
cohorts used, we conducted further analysis restricted to
the luminal-like BC subgroup.
PPP2R2A (B55α) expression defines luminal-like BC
groups with distinctive outcomes
When restricting the analysis to the luminal-like BC
subgroup, in the discovery cohort, 41.4% (n = 96) of the
cases display PPP2R2A (B55α) -/low expression, while in
the validation cohort, these tumors correspond to 42.3%
(n = 116) of luminal BC (Additional file 1: Table S5 and
Additional file 1: Table S6, respectively). Again, signifi-
cant associations with grade and PPP2R2A (B55α) ex-
pression status are found, with PPP2R2A (B55α)-/low
tumors displaying higher grade (p = 0.004). Luminal BCs
with PPP2R2A (B55α) -/low are also associated with a
higher prevalence of Her-2 overexpression (p < 0.001),
although no association with the Ki-67 proliferation
index was found (p = n.s.) (Additional file 1: Table S5).
PPP2R2A (B55α) -/ low expression status also defined
subgroups of luminal BCs with differential outcomes,
with PPP2R2A (B55α) -/ low-expressing BC associating
with worse DFS and OS (log-rank: p = 0.002 and p =
0.001, respectively (Figure 5). Despite considerable dif-
ferences in the baseline characteristics between luminal-
like cases in the discovery and validation cohorts,GA database, carcinomas harboring CNA (either HetDel or HomDel) at
.047).
Figure 5 Survival probability according to PPP2R2A (B55α) expression status. PPP2R2A (B55α)-/low carcinomas are associated with lower survival
probability: (a) OS probability in luminal BC patients of the discovery cohort (n = 232); (b) DFS probability in luminal BC patients of the discovery
cohort (n = 232); (c) OS probability in luminal BC patients of the validation cohort (n = 274); (d) DFS probability in luminal BC patients of the
validation cohort (n = 274).
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file 1: Table S7), the association between PPP2R2A
(B55α) expression status and worse DFS and OS was
further confirmed in this subset of patients in the valid-
ation cohort with PPP2R2A (B55α)-/ low BC (p = 0.031
for DFS and p = 0.027 for OS). In the luminal-like BC
subgroup, in both cohorts, PPP2R2A (B55α)-/ low is sig-
nificantly associated with steeper mortality curves, thus
further validating the scoring methodology used and the
association between PPP2R2A (B55α) expression status
and survival in this subset of patients (Figure 5).
PPP2R2A (B55α) -/low /Cyclin D1high expression defines a
group of luminal BC with worse outcomes
To address the secondary hypothesis that the combin-
ation of altered PPP2R2A (B55α) protein expression and
Cyclin D1 expression would define a group of luminal
BC with worse outcomes, we first evaluated Cyclin D1
expression in the luminal BC cases of the discoverycohort. In this cohort, the overexpression of Cyclin D1
is associated with higher grade carcinomas (p = 0.029),
but there was no significant association with any of the
survival outcomes (Additional file 1: Figure S2). Next,
we selected the cases with Cyclin D1 overexpression
from those with negative/low expression of PPP2R2A
(B55α), thus defining the phenotype PPP2R2A-/low/Cyclin
D1high. The prevalence of this phenotype is 11.9% in the
complete discovery cohort and 14.5% when restricting
luminal-like BC (Table 1). Interestingly, despite the associ-
ation with higher grade (p = 0.014) and Her-2 OE carcin-
omas (p = 0.020), 51.5% of the cases displaying the
phenotype PPP2R2A-/low/Cyclin D1high would be other-
wise classifiable as luminal A-like (Table 1) and the pres-
ence of the phenotype was also associated with both
worse OS (HR 2.71, 95% CI 1.17–6.28, p = 0.020) and
DFS (HR 2.63, 95% CI 1.26–5.11, p = 0.010) (Table 1 &
Figure 6). Since this effect on survival could be largely
dependent on HER2 status, disease stage and proliferation
Table 1 Discovery cohort - Clinico-pathological data of luminal-like BC patients
Parameter Status Total n=227 PPP2R2A (B55α)-/low




Age ≤ 50 91 14 (15.38) 77 (84.62) .767
> 50 136 19 (13.97) 117 (86.03)
n/a -
Size ≤ 2 cm 120 18 (15.00) 102 (85.00) .834
> 2 cm 107 15 (14.02) 92 (85.98)
n/a -
Grade I 63 3 (4.76) 60 (95.24) .014
II 108 17 (15.74) 91 (84.26)
III 55 13 (23.64) 42 (76.36)
n/a 1 1
Lymph node status LNN 105 14 (13.33) 91 (86.67) .306
Node pos. 103 18 (17.48) 85 (82.52)
n/a 19 1 18
PgR Positive 90 11 (12.22) 79 (87.78) .615*
Negative 10 2 (20.00) 8 (80.00)
n/a 127 78 51
HER2 Positive 29 9 (31.03) 20 (68.97) .020*
Negative 198 24 (12.12) 174 (87.88)
n/a -
KI-67 Index <14 152 18 (11.84) 134 (88.16) .125
≥14 60 12 (20.00) 48 (80.00)
n/a 15 3 12
Luminal subtype A-like 152 17 (11.18) 135 (88.82) .041
B-like 75 16 (21.33) 59 (78.67)
n/a -
DFS Num. of events 41 15 26 .002#
Mean (months) 91 92 89
OS Num. of events 30 9 21 .001#
Mean (months) 95 95 95
Abbreviations: LNN, Lymph node negative; PgR, Progesterone Receptor; HER2, human epidermal growth factor receptor-2.
*Fisher exact test p-value. # Log-Rank test p-value.
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ards survival analysis adjusting for HER2 status, tumor
size and lymph node status, after performing multiple im-
putation of missing values for lymph node status (more
information on modeling is provided in the Additional file
1). The proliferation index variable was dropped due to a
lack of significance in the univariate analysis using the set
cut-off of 14% (HR 1.88, 95% CI 0.84–4.19, p = 0.120 for
OS; Additional file 1: Figure S3). In this multivariate
model for PPP2R2A-/low/Cyclin D1high cases, the HR for
OS is 2.09 (95% CI 0.89–4.96, p = 0.091), and the HR for
DFS is 2.18 (95% CI 1.02–4.66, p = 0.043) (Table 2). Thus,
in luminal-like BC, the PPP2R2A-/low/Cyclin D1high
phenotype is significantly associated with worse DFS,independent of HER2 status, tumor size and lymph node
status (Table 2).
Discussion
Currently, the PP2A holoenzyme complex and certain
subunits including PPP2R2A (B55α) are thought to be
tumor suppressors in many cancer types [6,9,25,26].
However, the expression status of the PP2A holoenzyme
complex subunits, specifically PPP2R2A, as a biomarker
has hardly been explored in any cancer type, including
BC. Here, we present the first study to evaluate
PPP2R2A (B55α) expression in BC and show that CNA,
namely deletions centered on PPP2R2A in the most re-
cent TCGA Breast Cancer dataset, is associated with
Figure 6 Survival probability according to the phenotype defined by PPP2R2A (B55α) and Cyclin D1 expression status. Irrespective of other
clinicopathological features, in the luminal BC type, the PPP2R2A (B55α) -/low and Cyclin D1high phenotype associates with worse OS (a) and
worse DFS (b) (n = 227).
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sence of PPP2R2A (B55α) expression in BC is associated
with an aggressive phenotype, even in strikingly different
cohorts of patients.
In contrast to the lack of data on PPP2R2A (B55α),
there are numerous publications on the prognostic and
predictive roles of Cyclin D1 overexpression and
CCND1 amplification, which are usually associated with
early relapse and poor prognosis in ER-positive BC
[20,27-31]. Taking in account some of the reported char-
acteristics of the Integrative Cluster 2 BC [9,12], we hy-
pothesized that using a combined analysis of Cyclin D1
and PPP2R2A (B55α) expression assessed by IHC, we
would be able to identify an immunophenotype of lu-
minal BC that is associated with poor OS and DFS. In-
deed, we show that in luminal BC, the PPP2R2A-/low/
Cyclin D1high phenotype is associated with higher histo-
logical grade and concomitant HER-2 overexpression, as
well as shorter DFS and OS. Moreover, approximatelyTable 2 Univariate and multivariate hazard ratios for OS in lu
OS
Univariate
Variable HR (95% CI) p
PPP2R2A (B55α)-/low Cyclin D1high Present vs. Absent 2.71(1.17-6.28) .0
HER2 Positive vs. Negative 3.37(1.41-8.08) .0
Size >2cm vs.<2cm 5.19(1.95-13.85) .0
Lymph node status# LNN vs. Positive 4.13(1.47-11.58) .0
Ki-67 index >14% vs.≥14% 1.88(.84-4.19) .1
Abbreviations: LNN, Lymph node negative; PgR, Progesterone Receptor; HER2, hum
*Cox-proportional hazards model. #Results obtained after using multiple imputation
values were imputed adjusting for tumor size, the PPP2R2A (B55α)/Cyclin D1 phenohalf of the cases with the PPP2R2A-/low/Cyclin D1high
phenotype correspond to luminal B-like BC, which is
similar to the prevalence of luminal B BC in Integrative
Cluster 2 BC [12]. However, we also show that the asso-
ciation with worse DFS is independent of HER2-status,
as well as tumor size and lymph node status. Thus, we
provide additional clinicopathological support for the
role of PPP2R2A (B55α) as a tumor suppressor in BC
and present pilot evidence that the PPP2R2A-/low/Cyclin
D1high phenotype may be clinically relevant in BC and
should be further investigated.
We consider the PPP2R2A (B55α) scoring method-
ology proposed in our study to be fairly robust, as both
cohorts had similar proportions of cases assigned to the
various groups. Moreover, given the clinicopathological
differences between the cohorts, the PPP2R2A (B55α)
scoring methodology was able to define groups displaying
comparable magnitudes of HR, thus further reinforcing
the reproducibility of the method. Regarding Cyclin D1minal breast cancer patients (n=211)
DFS
Multivariate Univariate Multivariate
* HR (95% CI) p* HR (95% CI) p* HR (95% CI) p*
20 2.09(.89-4.96) .091 2.63(1.26-5.11) .010 2.18(1.02-4.66) .043
06 3.94(1.27-7.55) .013 3.02(1.37-6.68) .006 2.92(1.29-6.55) .010
01 3.64(1.39-11.18) .010 6.00(2.48-14.51) <.001 4.47(1.91-2.14) .001
07 2.49(0.84-7.34) .099 4.08(1.71-9.72) .002 2.36(.99-5.64) .052
2 - - 2.46(1.25-4.83) .009 - -
an epidermal growth factor receptor-2.
to deal with the 17 cases with missing values for Nodal disease. Nodal disease
type and HER2 status.
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the extensive validation of the IHC methodologies in the
literature [20,28,32,33]. However, some important limita-
tions remain. Although we did not directly demonstrate
the loss of B55α immunoreactivity in cases with known
deletions of the chr 8p21.2 region, we show that in the
TCGA Invasive Breast Cancer Dataset there is a strong
correlation between CNA and PPP2R2A (B55α) mRNA
expression in 736 BCs. Interestingly, in luminal-like BC
and other subtypes, multiple mechanisms could contrib-
ute to PPP2R2A (B55α) downregulation. In fact, recent re-
ports have shown that in BC, two inhibitors of PP2A, SET
and CIP2A are frequently overexpressed in triple negative,
basal and claudin-low subtypes [10]. Therefore, because
PPP2R2A (B55α) expression detected by IHC reflects not
only CNA, it could be a highly useful biomarker in BC, in-
cluding luminal-like BC. Despite controlling for major de-
terminants of BC survival, we were unable to determine if
this marker was prognostic or predictive because we did
not study the possible interactions between this phenotype
and treatment variables. Nonetheless, we achieved our ob-
jective of determining if it is possible to define an aggres-
sive subgroup of luminal-like BC based exclusively on the
phenotype assessed by IHC.
Conclusion
In conclusion, the results of this study show that CNAs in
the PPP2R2A gene and its expression are associated with
worse OS and that the PPP2R2A-/low/Cyclin D1high pheno-
type is associated with aggressiveness in luminal-like BC.
Importantly, not only does the PPP2R2A-/low/Cyclin D1high
phenotype add prognostic information to otherwise HER2-
expressing luminal BC, it also allows the identification of a
subgroup of luminal BC with reduced DFS that would be
otherwise classified as luminal A-like. Consequently, these
results provide one of the first indications for the clinical
relevance of this phenotype in human BC. Based on the
functional characteristics and cancer-specific expression
pattern of PPP2R2A (B55α) and Cyclin D1, it is evident
that both PPP2R2A and the PPP2R2A-/low/Cyclin D1high
phenotype deserve further attention to better uncover their
possible clinical and biological importance in BC.
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